ACLX-10.06%8.3%
BBOT+2.71%8.3%
BMY+39.84%8.3%
CMPX-20.53%8.3%
GMAB+35.70%8.3%
JAZZ+106.55%8.3%
KURA+55.42%8.3%
LEGN-38.64%8.3%
NRIX+163.51%8.3%
NUVL0.00%8.3%
RVMD+465.96%8.3%
ZYME+89.87%8.3%
As of Aug 24, 2026, 4:53 AM ET
Biotech '26: Scalable Oncology Drugs Constituents
Arcellx, Inc.ACLX | 8.3% | 0.00% | 0.00% | 0.00% | 0.00% | -1.67% | 0.00% | -4.64% | -7.60% | 281.61% | -10.06% | $3.75B |
BridgeBio Oncology Therapeutics Inc.BBOT | 8.3% | 0.00% | -1.30% | 2.95% | 12.24% | -27.48% | -9.47% | -9.20% | -9.20% | -9.20% | 2.71% | $727.4M |
Bristol-Myers Squibb CompanyBMY | 8.3% | 2.35% | 5.35% | 7.92% | 2.60% | 24.23% | 7.44% | 13.65% | 42.40% | 11.14% | 39.84% | $136.88B |
Compass Therapeutics, Inc.CMPX | 8.3% | 1.69% | 9.09% | 15.94% | 25.65% | -55.31% | -57.52% | 42.01% | 90.48% | -40.00% | -20.53% | $432.2M |
Genmab A/SGMAB | 8.3% | 0.12% | 8.43% | 15.86% | 15.86% | 8.60% | 13.62% | 77.74% | 22.35% | -31.14% | 35.70% | $20.54B |
Jazz Pharmaceuticals plcJAZZ | 8.3% | 2.24% | 2.54% | 0.16% | 0.56% | 49.58% | 33.82% | 101.11% | 123.31% | 82.88% | 106.55% | $15.97B |
Kura Oncology, Inc.KURA | 8.3% | 1.54% | 19.74% | 14.44% | 31.96% | 14.44% | 36.20% | 82.36% | -41.08% | -32.21% | 55.42% | $1.06B |
Legend Biotech CorporationLEGN | 8.3% | 2.63% | -0.05% | -1.80% | 17.63% | 0.37% | 14.84% | -34.36% | -62.05% | -42.09% | -38.64% | $4.04B |
Nurix Therapeutics, Inc.NRIX | 8.3% | -1.22% | 2.93% | 14.29% | 15.12% | 40.85% | 67.31% | 134.80% | 11.24% | -18.04% | 163.51% | $2.77B |
Nuvalent, Inc.NUVL | 8.3% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -24.14% | 0.00% | $1.62B |
Revolution Medicines, Inc.RVMD | 8.3% | -1.07% | 1.90% | 10.69% | 11.69% | 162.98% | 105.31% | 505.38% | 379.97% | 705.93% | 465.96% | $44.53B |
Zymeworks Inc.ZYME | 8.3% | 7.90% | 17.89% | 25.42% | 30.67% | 8.89% | 23.10% | 140.52% | 151.71% | -12.83% | 89.87% | $2.11B |
| Theme return | — | 1.35% | 5.54% | 8.27% | 13.56% | 21.81% | 23.21% | 84.82% | 63.37% | 115.23% | 67.59% | — |
| Average | 8.3% | 1.35% | 5.54% | 8.82% | 13.67% | 18.79% | 19.55% | 87.45% | 58.46% | 72.66% | 74.19% | $19.54B |
| Median | 8.3% | 0.83% | 2.74% | 9.31% | 13.68% | 8.75% | 14.23% | 59.88% | 16.79% | -15.43% | 37.77% | $3.26B |
| Std Dev | 0.0% | 2.34% | 6.73% | 8.26% | 11.04% | 51.01% | 38.60% | 137.79% | 114.70% | 209.72% | 130.76% | $37.49B |
| Min | 8.3% | -1.22% | -1.30% | -1.80% | 0.00% | -55.31% | -57.52% | -34.36% | -62.05% | -42.09% | -38.64% | $432.2M |
| Max | 8.3% | 7.90% | 19.74% | 25.42% | 31.96% | 162.98% | 105.31% | 505.38% | 379.97% | 705.93% | 465.96% | $136.88B |
| % Positive Tickers | 58.33% | 66.67% | 75.00% | 83.33% | 66.67% | 66.67% | 66.67% | 58.33% | 33.33% | 66.67% |
Default: Wgt ↓ · Click headers to sort · Shift+click secondary
About this theme
Biotech '26: Scalable Oncology Drugs tracks 12 publicly listed stocks in this theme: ACLX, BBOT, BMY, CMPX, GMAB, JAZZ, KURA, LEGN, NRIX, NUVL, RVMD, ZYME. See the constituent table for details.